logo

For the Inventor, By the Inventor

Suwanee, GA, United States of America

Lee K Hoong

This inventor holds 4 USPTO granted patents. Top assignee: Atherogenics, Inc.. Active years: 2003-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lee K Hoong. Retrieved from https://idiyas.com/inventor/lee-k-hoong

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4

% Patents Active = 25.0

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 45(Granted Patents)


Company Filing History:

goldMedal4 out of 25 
 
Atherogenics, Inc.
 patents

Years Active: 2003-2006

Loading Chart...
4 patents (USPTO):Explore Patents
1. 7078431 - 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders (2006-07-18),
2. 6852878 - Thioketals and thioethers for inhibiting the expression of VCAM-1 (2005-02-08),
3. 6747061 - N-substituted dithiocarbamates for the treatment of biological disorders (2004-06-08),
4. 6608101 - 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders (2003-08-19),

Title: Innovations of Lee K Hoong in VCAM-1 Mediated Disorders

Introduction

Lee K Hoong is an accomplished inventor based in Suwanee, GA (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target VCAM-1 mediated disorders. With a total of four patents to his name, his work has the potential to impact various inflammatory and autoimmune diseases.

Latest Patents

Among his latest patents, Lee K Hoong has developed 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders. These compounds have been discovered to inhibit the expression of VCAM-1, making them useful in treating a range of disorders such as arthritis, asthma, and multiple sclerosis. Another notable patent involves thioketals and thioethers that also inhibit VCAM-1 expression, which can be applied in treating cardiovascular diseases, neurological disorders, and even cancer.

Career Highlights

Lee K Hoong is currently associated with Atherogenics, Inc., where he continues to innovate in the field of therapeutic compounds. His research focuses on developing treatments that can alleviate the symptoms of various inflammatory disorders and improve patient outcomes.

Collaborations

Lee has collaborated with notable colleagues, including Charles Q Meng and Liming Ni, who contribute to his research efforts and advancements in the field.

Conclusion

Lee K Hoong's innovative work in developing compounds for treating VCAM-1 mediated disorders showcases his dedication to improving healthcare through scientific research. His contributions are paving the way for new therapeutic options in the medical field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…